The growing application demand of
vaccine adjuvants market in vaccination and the rising prevalence of zoonotic & infectious diseases along with increasing geriatric population base are the major drivers, which are anticipated to propel the global market demand over the study period. The new report added by DecisionDatabases.com
“Global Vaccine Adjuvants Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast” offers the complete industry landscape covering the trends, development trends and future market growth.
The adjuvants are immunological agents which help in directing and synergizing the immune response to the vaccine agents. They are mainly classified on the basis of their physical or chemical properties, source and action mechanism into three groups - carriers, vehicle adjuvants, and immune-stimulants. Vaccine adjuvants improve the immune response against specific antigens. Additionally, increasing numbers of livestock along with rising occurrence of diseases and growing government attention on immunization programs will further aid in the growth of the market in the near future. Rapid technological advancements in aluminum based adjuvants and increasing focus on the development & discovery of vaccine adjuvants are also anticipated to fuel market demand during the forecast period. However, increasing expenses on adjuvant research and stringent regulatory frameworks towards products approval & environmental concerns are major challenges, which can negatively affect the growth of the market in the forthcoming years. The rise in the number of acquisitions and collaborations by private organizations and rising funding by government bodies for R&D are estimated to open new growth avenues in the study period.
The global market has been segmented based on product types into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants and others. The adjuvant emulsions is a fastest growing segment and are projected to witness a double-digit growth over the forecast period owing to the as rising occurrence of diseases such as cancer, allergy and HIV/AIDS, increasing demand for technologically advanced treatment alternatives, and growth of better vaccine immunization. The market has been further segmented based on the route of administration into oral, subcutaneous, intranasal, intramuscular, intradermal and others. The intramuscular segment is expected to grow at a significant rate over the coming years due to the rapidly increasing aging population and growing demand for vaccines for improved immunization across the globe. Furthermore, the market has been segmented based on disease type, applications, and applications category. The infectious diseases segment has accounted for major market share and is expected to grow at the highest CAGR over the forecast period on account of rising prevalence of infectious diseases and favorable government & organizations initiatives, globally. The research applications segment is expected to witness a double-digit growth in the study period owing to the continuous research projects for the development of new adjuvants, rising initiatives by organizations & government bodies, growing commercial usage of various vaccine adjuvants, and rising incidences of zoonotic diseases worldwide. The human vaccine adjuvants is a leading applications category segment and are projected to account for the largest market share over the coming years on account of rising favorable initiatives by companies & governments to spread awareness about the vaccination across the globe.
North America is a major market for vaccine adjuvants and is estimated to continue its dominance during the forecast period owing to the rising prevalence of various infectious & zoonotic diseases along with the increasing aging population in the region.
The key industry players include Brenntag Biosector A/S, Seppic, CSL Limited, Agenus, Inc., Novavax, Inc., Invivogen, SPI Pharma, Inc., Avanti Polar Lipids, Inc., MPV Technologies, Inc., and OZ Biosciences.
In Feb 2015, Novavax has launched the first human trial of its 4th recombinant Ebola vaccine in Australia
In Nov 2015, The U.S.F.D.A (Food and Drug Administration) has approved “Fluad”, the first recurring influenza vaccine adjuvant. It is a trivalent vaccine used for the prevention of seasonal influenza in older people.
In July 2016, NIAID (The National Institute of Allergy and Infectious Diseases), has started an early-stage clinical trial of a vaccine adjuvant, which is used to prevent from yellow fever virus.
About-Us:
DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.
Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise and meaningful data at a lightning speed.
For more details:
DecisionDatabases.com
E-Mail:
[email protected]
Phone: +91 99 28 237112
Web: www.decisiondatabases.com/
